Zafgen, a clinical-stage biotech developing a treatment for obesity, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol ZFGN. Zafgen initially filed confidentially on January 31, 2014. Leerink Partners and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
